Icon

TAXOL (nda020262)- (6MG/ML)

PACLITAXEL HQ SPCLT PHARMA
6MG/ML
Yes No
2013-Mar-09 Expired
None None
None No
TAXOL is indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, TAXOL is indicated in combination with cisplatin. TAXOL is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
9 0 6
Total Other Developers 1
Drugs with Suitability No
6MG/ML ** ** - - -
NDA Sales Available Total Generic Sales Available
No 6
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** ****** ************ *.*. *********** ******** *, *******, **** **, *********** (***) ***
****** ******* ******* ********* *** *** *********** *-** ***** **, ********, ******** ****, ********* (***) ***
****** ******* ****** *******, *** *** *********** **** ******** ******, *****, ** *** ***, ****** (***) ***
****** ******* ****** ******* **** *** *********** ***** ******* *, **********, *-*****, ******* (***) ***
****** ******* ***-***** **** *** *********** **********. **, *************, *****, ******* (***) ***
****** ********* **** *** ********* **** ***, *** *********** **** *. **** ****** **** ***** ********* ******, ******* ****, ******** (**) *****, ****** ****** (***) ***
****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***
****** ******* ******* *************** ******* *********** ****** **. **,** *** **, *******, ****** *****, **********, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.